Appl. No. Filed

5,665,728

: September 20, 2000

least one biological activity of the polypeptide encoded by clone P00210_D09 (SEQ ID NO: 2);

(e) a polynucleotide encoding at least about 50 contiguous amino acids from amino acids 22 to 122 of SEQ ID NO: 1, wherein said polynucleotide encodes a polypeptide having at least one biological activity of the polypeptide encoded by clone P00210 D09 (SEQ ID NO: 2);

(f) a polynucleotide encoding at least about 50 contiguous amino acids from amino acids 56 to 122 of SEQ ID NO: 1, wherein said polynucleotide encodes a polypeptide having at least one biological activity of the polypeptide encoded by clone P00210 D09 (SEQ ID NO: 2);

- (g) a polynucleotide of SEQ ID NO: 2; and
- (h) the complement of a polynucleotide of (a) (g).

REMARKS

Claims 1-8 are pending in this application. Claims 9-29 have been canceled without, prejudice.

The Restriction Requirement

Applicants were requested to elect, for examination purposes, the invention of one of Groups I-XII, listed on pages 2-3 of the Office Action. The invention of Group I (Claims 1-8) drawn to nucleic acids encoding a polypeptide having the sequence of SEQ ID NO:1 or hybridizing under stringent conditions with the complement of the coding region of SEQ ID NO: 2 or the complements thereof, are hereby elected, with traverse. Claims 9-29 have been canceled to reflect this election.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."